Ovarian epithelial cancer metastatic – Diagnostics – Overview of Information and Clinical Research

Discovering metastatic ovarian epithelial cancer requires a thoughtful approach that combines physical examination, laboratory tests, and advanced imaging to understand where the disease has spread and guide treatment decisions.

Introduction: Who Should Undergo Diagnostics

Metastatic ovarian epithelial cancer, also known as stage IV ovarian cancer, means the disease has spread beyond the ovaries to distant parts of the body such as the liver, lungs, or even bones. Because ovarian cancer often develops quietly without causing noticeable symptoms in its early stages, many people do not discover they have the disease until it has already progressed to an advanced stage. This makes understanding when to seek diagnostic testing particularly important.^[1]

If you experience persistent symptoms that do not improve with time or simple treatments, it is advisable to seek medical attention promptly. Common signs that should prompt you to see a doctor include ongoing abdominal pain or bloating, difficulty eating or feeling full very quickly after starting a meal, nausea and vomiting, or pelvic pain that does not go away. Other symptoms might include changes in bowel habits, a strong urge to urinate frequently, or unexpected vaginal bleeding. These symptoms can easily be confused with less serious digestive problems like gas or constipation, which is one reason ovarian cancer is often detected late.^[3]^[7]

Women who have certain risk factors should be especially attentive to any unusual symptoms. If you have a family history of ovarian cancer or breast cancer, particularly in close relatives like your mother, daughter, or sister, your chances of developing ovarian cancer are higher. Inherited changes in genes called BRCA1 or BRCA2 significantly increase the risk of both breast and ovarian cancer. Other hereditary conditions, such as Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer), also raise ovarian cancer risk. Additional risk factors include endometriosis, obesity, older age, and certain reproductive factors.^[4]^[5]

Regular examinations with a gynecologist are important for early detection of epithelial ovarian cancer. While there is currently no screening test proven to improve early detection and outcomes for people with ovarian cancer, routine pelvic exams and paying close attention to your body’s signals remain critical. If your doctor suspects ovarian cancer based on your symptoms or risk factors, they will recommend a series of diagnostic tests to confirm the diagnosis and determine the stage of the disease.^[1]^[16]

⚠️ Important

Ovarian cancer symptoms are often vague and can resemble common digestive issues. If you experience persistent bloating, abdominal pain, difficulty eating, or pelvic discomfort lasting more than a few weeks, do not dismiss these signs. Seeking medical evaluation early can make a significant difference in diagnosis and treatment outcomes.

Diagnostic Methods for Identifying Metastatic Ovarian Epithelial Cancer

Diagnosing metastatic ovarian epithelial cancer involves multiple steps and different types of tests. The goal is not only to confirm that cancer is present but also to understand how far it has spread throughout the body. This information helps doctors create the most effective treatment plan for each individual patient.

Physical Examination

The diagnostic process typically begins with a thorough physical examination. Your doctor will perform a pelvic examination to feel for any abnormal masses or enlargement of the ovaries. During this exam, the doctor inserts gloved fingers into the vagina while pressing on the abdomen with the other hand to check the size, shape, and position of the ovaries and uterus. A digital rectal exam may also be performed to check for abnormal growths behind the uterus or in the lower pelvis. While these exams can detect abnormalities, they cannot definitively confirm cancer.^[1]^[4]

Blood Tests and Tumor Markers

Blood tests play an important role in diagnosing ovarian cancer. The most commonly used blood test measures a protein called CA-125, which is often elevated in people with epithelial ovarian cancer. However, CA-125 levels can also be raised by other conditions such as endometriosis, pelvic inflammatory disease, or even menstruation, so an elevated CA-125 alone does not confirm cancer. Despite this limitation, CA-125 testing is valuable for monitoring disease progression and response to treatment once cancer has been diagnosed.^[1]

Imaging Studies

Imaging tests are essential for visualizing tumors and determining whether cancer has spread to distant organs. Several types of imaging may be used:

Transvaginal ultrasound: This test uses sound waves to create pictures of the ovaries and surrounding structures. A small probe is inserted into the vagina to get a closer view of the ovaries. Ultrasound can help identify masses or cysts on the ovaries, but it cannot determine whether a mass is cancerous or benign.
Computed tomography (CT) scans: CT scans use X-rays to create detailed cross-sectional images of the body. They are particularly useful for detecting cancer that has spread to the abdomen, pelvis, chest, liver, or lymph nodes. CT scans help doctors see the size and location of tumors and plan surgical approaches.
Magnetic resonance imaging (MRI): MRI uses magnetic fields and radio waves to produce detailed images of soft tissues. It can provide additional information about the extent of disease, especially in complex cases.
Positron emission tomography (PET) scans: PET scans involve injecting a small amount of radioactive sugar into the body. Cancer cells, which use more sugar than normal cells, show up as bright spots on the scan. PET scans can help identify areas of active cancer throughout the body.
Chest X-rays: A simple chest X-ray can detect fluid buildup in the lungs, known as pleural effusion, which may occur when cancer spreads to the lining of the lungs. This finding indicates stage IV disease.^[4]^[23]

Biopsy and Tissue Diagnosis

While imaging and blood tests can suggest the presence of cancer, a definitive diagnosis requires examining tissue under a microscope. This is done through a biopsy, which involves removing a small sample of tissue for laboratory analysis. In ovarian cancer, biopsies are often obtained during surgery rather than beforehand. Your doctor may not be able to tell you the exact stage of your cancer until surgery is performed and tissue samples are analyzed.^[1]^[4]

During surgery, the surgeon will examine the ovaries, fallopian tubes, uterus, and surrounding organs. They will also check the peritoneum (the lining of the abdominal cavity), lymph nodes, and other areas where cancer commonly spreads. Tissue samples are taken from multiple sites to determine the extent of disease. The pathologist examines these samples to confirm the diagnosis of epithelial ovarian cancer and identify the specific subtype, such as high-grade serous carcinoma, endometrioid carcinoma, clear cell carcinoma, or mucinous carcinoma.^[3]

Additional Diagnostic Procedures

In some cases, additional procedures may be necessary to fully assess the extent of cancer spread:

Paracentesis: If fluid has accumulated in the abdomen (a condition called ascites), a needle may be inserted through the abdominal wall to remove some fluid for testing. The fluid is examined for cancer cells.
Thoracentesis: Similarly, if fluid has collected around the lungs, a needle can be used to remove fluid from the chest cavity for analysis. Finding cancer cells in this fluid confirms stage IV disease.^[6]^[23]

Distinguishing Metastatic Ovarian Cancer from Other Conditions

Distinguishing ovarian cancer from other gynecological conditions is an important part of the diagnostic process. Benign ovarian cysts, endometriosis, pelvic inflammatory disease, and fibroids can all cause similar symptoms. Imaging studies and tumor marker tests help differentiate these conditions. Additionally, the pattern of spread seen on imaging can provide clues. Ovarian cancer typically spreads first to nearby structures in the pelvis and abdomen, then to the peritoneum, lymph nodes, and eventually to distant organs like the liver and lungs.^[1]^[2]

Epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer form in the same type of tissue and behave similarly. Because of this, they are diagnosed and treated in the same way. Experts believe that many ovarian cancers actually start in cells at the end of the fallopian tube and then spread to the ovary. Primary peritoneal cancer forms in the peritoneum itself rather than starting in the ovary, but it looks and acts like ovarian cancer.^[4]^[5]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments for cancer. Many people with metastatic ovarian epithelial cancer may be eligible to participate in clinical trials, which can provide access to cutting-edge therapies that are not yet widely available. However, enrolling in a clinical trial requires meeting specific criteria, and diagnostic tests play a key role in determining eligibility.

Standard Diagnostic Requirements

To qualify for most clinical trials for metastatic ovarian cancer, patients must undergo a comprehensive set of diagnostic tests. These tests serve several purposes: they confirm the diagnosis, determine the stage and extent of disease, assess overall health status, and identify specific characteristics of the tumor that may make certain treatments more or less likely to work.

Common diagnostic requirements for clinical trial enrollment include:

Histological confirmation: Tissue samples must be reviewed by a pathologist to confirm the diagnosis of epithelial ovarian cancer and identify the subtype. The pathology report provides critical information about the cancer cells’ appearance and behavior.
Staging information: Clinical trials often require patients to have a specific stage of disease. For metastatic (stage IV) ovarian cancer trials, imaging studies must demonstrate that cancer has spread to distant organs such as the liver, lungs, or other sites outside the pelvis and abdomen.
Performance status assessment: Doctors evaluate how well patients can perform daily activities using standardized scales. This helps determine whether a patient is strong enough to tolerate experimental treatments.
Blood tests: Routine blood work checks kidney function, liver function, blood cell counts, and other markers of overall health. Abnormal results may exclude patients from certain trials if the experimental treatment could worsen existing problems.

Molecular and Genetic Testing

Modern clinical trials increasingly focus on targeted therapies that work against specific molecular features of cancer cells. As a result, molecular and genetic testing has become an important part of clinical trial diagnostics. These tests analyze tumor tissue or blood samples to look for genetic mutations, protein expression patterns, or other molecular markers that predict response to specific treatments.^[10]

For epithelial ovarian cancer, some of the most important molecular tests include:

BRCA1 and BRCA2 mutation testing: These genes help repair damaged DNA in cells. When they are mutated, cells become more vulnerable to certain types of damage. Patients with BRCA mutations may be eligible for trials testing drugs called PARP inhibitors, which exploit this vulnerability to kill cancer cells. About 10 to 15 percent of epithelial ovarian tumors have BRCA mutations.^[1]^[5]
Homologous recombination deficiency (HRD) testing: This test looks for broader problems with DNA repair beyond just BRCA mutations. Tumors with HRD may also respond well to PARP inhibitors and other targeted treatments.^[14]
Microsatellite instability (MSI) and mismatch repair deficiency (dMMR) testing: These tests identify tumors with specific DNA repair defects. Patients with MSI-high or dMMR tumors may be eligible for immunotherapy trials using checkpoint inhibitor drugs.^[16]^[22]
Folate receptor alpha testing: Some ovarian cancers produce high levels of a protein called folate receptor alpha on their cell surfaces. Patients whose tumors test positive for this marker may be eligible for trials of antibody-drug conjugate treatments that target this protein.^[14]

⚠️ Important

Genetic testing for BRCA mutations and other inherited cancer risk genes is important not just for treatment decisions but also for family members. If you are diagnosed with ovarian cancer, genetic counseling and testing can help determine whether your relatives have increased cancer risk and would benefit from enhanced screening or preventive measures.

Imaging for Treatment Response Monitoring

Clinical trials require regular monitoring to assess whether experimental treatments are working. Baseline imaging studies are performed before treatment begins, establishing a starting point for comparison. Follow-up scans are then done at specified intervals throughout the trial to measure changes in tumor size and determine whether the disease is responding, remaining stable, or progressing. CT scans and PET scans are commonly used for this purpose.^[4]

Tumor Marker Monitoring

CA-125 levels are often monitored throughout clinical trials as an indicator of treatment response. Rising CA-125 levels may suggest disease progression, while falling levels may indicate that treatment is working. However, changes in CA-125 levels do not always match imaging findings, so both types of monitoring are typically used together.^[1]

Participating in clinical trials offers patients access to promising new treatments while contributing to medical knowledge that will help future patients. The diagnostic requirements for trials are designed to ensure patient safety and to select patients most likely to benefit from the experimental treatment being studied. If you are interested in clinical trials, discuss this option with your oncologist, who can help determine whether you meet the criteria for any available studies.^[4]

Prognosis and Survival Rate

Prognosis

The prognosis for metastatic ovarian epithelial cancer depends on several individual factors including your age, overall health, how well your cancer responds to treatment, and what treatment options are available to you. When ovarian cancer is diagnosed at stage IV, it means the disease has spread to distant organs such as the liver, lungs, bones, or lymph nodes outside the abdomen. This advanced stage presents significant treatment challenges, though treatment can often help patients feel better and potentially live longer.^[7]^[18]

High-grade serous carcinoma, the most common and aggressive subtype of epithelial ovarian cancer, accounts for three out of four cases. Nearly 70 percent of high-grade serous cases are diagnosed at stage III or IV because this cancer tends to spread quickly once it reaches the ovaries. Different subtypes of epithelial ovarian cancer can lead to different outcomes. For example, clear cell carcinoma often does not respond well to chemotherapy, while endometrioid carcinoma tends to respond better to standard treatments.^[3]^[15]

Even in advanced stages, it is possible in some cases for ovarian cancer to be treated successfully. Treatment for metastatic disease typically includes some combination of surgery, chemotherapy, and targeted medications. While cure is not common at stage IV, approximately 20 percent of people with late-stage ovarian cancer survive more than 12 years after treatment and are considered cured in medical terms.^[18]

Survival Rate

Five-year relative survival rates compare the chances that someone with a certain stage and type of cancer will survive for at least five years compared with people in the general population who do not have that cancer. For people initially diagnosed with stage IV epithelial ovarian cancer, the five-year relative survival rate is 31 percent. This means that people diagnosed with stage IV epithelial ovarian cancer are about 31 percent as likely to live at least five years as someone without this cancer.^[7]

For other types of ovarian cancer diagnosed at stage IV, survival rates differ. Germ cell tumors of the ovary have a five-year relative survival rate of 71 percent at stage IV, while ovarian stromal tumors have a rate of 70 percent. These rates are based on data from people diagnosed between 2012 and 2018, and survival rates typically improve over time as better treatments become available.^[7]

Patients diagnosed with earlier stages of ovarian cancer have considerably better outcomes. Those diagnosed with stage I ovarian cancer have a five-year survival rate of 90 percent, while stage II has a rate of 70 percent. Stage III, where cancer has spread within the abdomen but not to distant organs, has a five-year survival rate of 39 percent. However, only about 20 percent of ovarian cancers are detected before the disease spreads beyond the ovaries.^[2]^[7]^[16]

It is important to remember that survival statistics represent large groups of patients and do not predict any individual person’s outcome. Your doctor can provide a more personalized estimate based on your specific situation, including the subtype of your cancer, genetic factors, your response to treatment, and your overall health. Many factors influence survival, and some people live much longer than average statistics would suggest.^[7]^[18]

#1 Clinical Trials Search in Europe